[go: up one dir, main page]

TW201925204A - 稠合三環化合物 - Google Patents

稠合三環化合物 Download PDF

Info

Publication number
TW201925204A
TW201925204A TW107141391A TW107141391A TW201925204A TW 201925204 A TW201925204 A TW 201925204A TW 107141391 A TW107141391 A TW 107141391A TW 107141391 A TW107141391 A TW 107141391A TW 201925204 A TW201925204 A TW 201925204A
Authority
TW
Taiwan
Prior art keywords
compound
alkyl
methyl
mmol
group
Prior art date
Application number
TW107141391A
Other languages
English (en)
Chinese (zh)
Inventor
中尾彰
森誠
宮崎理樹
山口曉丈
小倉義浩
秋生麻由子
河村明日香
早川美穗
宮崎正二郎
石濱壽紘
Original Assignee
日商第一三共股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商第一三共股份有限公司 filed Critical 日商第一三共股份有限公司
Publication of TW201925204A publication Critical patent/TW201925204A/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW107141391A 2017-11-22 2018-11-21 稠合三環化合物 TW201925204A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017225151 2017-11-22
JP2017-225151 2017-11-22

Publications (1)

Publication Number Publication Date
TW201925204A true TW201925204A (zh) 2019-07-01

Family

ID=66631976

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107141391A TW201925204A (zh) 2017-11-22 2018-11-21 稠合三環化合物

Country Status (2)

Country Link
TW (1) TW201925204A (fr)
WO (1) WO2019103060A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021238963A1 (fr) * 2020-05-28 2021-12-02 杭州中美华东制药有限公司 Procédé de préparation de sel de diacide de propanoate de méthyle (s)-2-amino-3-(4-(2,3-diméthylpyridine-4-yl)phényl)
WO2021238965A1 (fr) * 2020-05-28 2021-12-02 杭州中美华东制药有限公司 Procédé de préparation de méthyl (s)-2-amino-3-(4-(2,3-diméthylpyridin-4-yl)phénylpropionate et son sel
WO2022262143A1 (fr) * 2021-06-17 2022-12-22 杭州中美华东制药有限公司 Procédé de préparation de borate de pyridine
WO2025189141A1 (fr) 2024-03-08 2025-09-12 Annapurna Bio, Inc. Méthodes de traitement de l'obésité et d'augmentation de la perte de poids

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115667268B (zh) * 2020-05-28 2024-09-24 杭州中美华东制药有限公司 一种glp-1受体激动剂游离碱的制备方法
US20240374587A1 (en) 2021-09-08 2024-11-14 Shionogi & Co., Ltd. Medicine for prevention and treatment of diseases linked to anti-obesity activity
WO2025057134A2 (fr) 2023-09-14 2025-03-20 Ascletis Pharma (China) Co., Limited Agoniste de glp-1r et méthode thérapeutique associée
US12291530B1 (en) 2023-11-24 2025-05-06 Ascletis Pharma (China) Co., Limited GLP-1R agonist and therapeutic method thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1147094A1 (fr) * 1999-01-15 2001-10-24 Novo Nordisk A/S Agonistes non peptidiques de glp-1
WO2009111700A2 (fr) * 2008-03-07 2009-09-11 Transtech Pharma, Inc. Oxadiazoanthracènes pour le traitement du diabète
BRPI1013579A2 (pt) * 2009-03-30 2020-11-03 Transtech Pharma, Inc. derivados de azoantraceno substituídos, composições farmacêuticas e métodos de uso dos mesmos

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021238963A1 (fr) * 2020-05-28 2021-12-02 杭州中美华东制药有限公司 Procédé de préparation de sel de diacide de propanoate de méthyle (s)-2-amino-3-(4-(2,3-diméthylpyridine-4-yl)phényl)
WO2021238965A1 (fr) * 2020-05-28 2021-12-02 杭州中美华东制药有限公司 Procédé de préparation de méthyl (s)-2-amino-3-(4-(2,3-diméthylpyridin-4-yl)phénylpropionate et son sel
CN115667219A (zh) * 2020-05-28 2023-01-31 杭州中美华东制药有限公司 一种(s)-2-氨基-3-(4-(2,3-二甲基吡啶-4-基)苯基)丙酸甲酯二酸盐的制备方法
CN115697968A (zh) * 2020-05-28 2023-02-03 杭州中美华东制药有限公司 (s)-2-氨基-3-(4-(2,3-二甲基吡啶-4-基)苯基丙酸甲酯及其盐的制备方法
CN115697968B (zh) * 2020-05-28 2024-03-29 杭州中美华东制药有限公司 (s)-2-氨基-3-(4-(2,3-二甲基吡啶-4-基)苯基丙酸甲酯及其盐的制备方法
WO2022262143A1 (fr) * 2021-06-17 2022-12-22 杭州中美华东制药有限公司 Procédé de préparation de borate de pyridine
WO2025189141A1 (fr) 2024-03-08 2025-09-12 Annapurna Bio, Inc. Méthodes de traitement de l'obésité et d'augmentation de la perte de poids

Also Published As

Publication number Publication date
WO2019103060A1 (fr) 2019-05-31

Similar Documents

Publication Publication Date Title
TW201925204A (zh) 稠合三環化合物
EP4025574B1 (fr) Composés inhibiteurs de rip1 et leurs procédés de fabrication et d'utilisation
TWI858848B (zh) ErbB受體抑制劑
CN112979524B (zh) 作为雌激素受体调节剂的6,7-二氢-5h-苯并[7]轮烯衍生物
CN105636953B (zh) 1,4‑二取代的哒嗪衍生物及其用于治疗与smn缺乏相关的病症的用途
CN118647620A (zh) 用于治疗癌症的环状2-氨基-3-氰基噻吩及其衍生物
WO2023046034A1 (fr) Composé hétérocyclique contenant de l'azote, son procédé de préparation, intermédiaire de celui-ci et application de celui-ci
WO2020064002A1 (fr) Composé d'isoindoline, procédé de préparation, composition pharmaceutique et utilisation associée
WO2018143315A1 (fr) Composé de quinazoline
WO2015158310A1 (fr) Inhibiteur de tyrosine kinase et ses utilisations
CN118221685A (zh) 作为kras g12d抑制剂的吲哚类化合物
TW202045512A (zh) 新型雜環三環衍生物化合物及其用途
WO2016169504A1 (fr) Dérivé pyrimidylamino à cycle condensé, son procédé de préparation, et intermédiaire, composition pharmaceutique et applications associées
WO2022100623A1 (fr) Composés thiophène hétérocycliques substitués par azote et leur utilisation
TW201602105A (zh) 雜環化合物
TW201625533A (zh) Kcnq 2至5通道活化劑
KR20220018475A (ko) Ep300 또는 cbp 조절 및 이의 표시를 위한 응축 아진
TW202430522A (zh) 一種用於bcl-2蛋白靶向降解的嵌合體化合物、其製備方法及其在醫藥上的應用
WO2020103769A1 (fr) Composés de dioxane-quinazoline ou dioxane-quinoléine liés à un cycle aromatique, compositions et utilisation associées
TWI691332B (zh) 噻唑烷酮化合物及其用途
WO2019192533A1 (fr) Agent de dégradation du récepteur des œstrogènes pour le traitement du cancer du sein
WO2019129114A1 (fr) Inhibiteurs de l'indoléamine 2,3-dioxygénase et leur utilisation en médecine
WO2021115495A1 (fr) Composé hétérocyclique contenant du soufre à petites molécules
BR112021009378A2 (pt) espiro-compostos heterocíclicos como inibidores de receptor de am2
WO2023098825A1 (fr) Inhibiteur de sos1, composition pharmaceutique le comprenant et son utilisation